Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 5, 2011, Pages 300-310

  Graefe Mody, E U ^a   Brand, T ^a   Ring, A ^a   Withopf, B ^a   Stangier, J ^a   Iovino, M ^a   Woerle, H J ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Drug interaction; Linagliptin; Type 2 diabetes; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; LINAGLIPTIN; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG HALF LIFE; ENANTIOMER; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PROTHROMBIN TIME; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN;

ADULT; ANTICOAGULANTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALF-LIFE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROTHROMBIN TIME; PURINES; QUINAZOLINES; SOFTWARE; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; WARFARIN; YOUNG ADULT;

EID: 79955980589     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201507     Document Type: Article

References (37)

1. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methylquinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008; 325: 175-182. (Pubitemid 351439162)
2. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008; 48: 1171-1178.
3. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3- methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro- purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther. 2009; 328: 556-563.
4. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009; 11: 786-794.
5. Graefe-Mody EU, Padula S, Ring A, Withopf B, Dugi KA. Evaluation of the potential for steadystate pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects. Curr Med Res Opin. 2009; 25: 1963-1972.
6. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010; 19: 133-140.
7. Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, Fuchs H. Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos. 2009; 30: 422-436.
8. Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. J Clin Pharmacol. 2010; 50: 873-885.
9. Retlich S, Duval V, Ring A, Staab A, Hüttner S, Jungnik A, et al. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg - 10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male volunteers. Clin Pharmacokinet. 2010; 49: 829-840.
10. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010; 38: 667-678.
11. Graefe-Mody U, Huettner S, Stähle H, Ring A, Dugi KA. Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin. Int J Clin Pharmacol Ther. 2010; 48: 367-374.
12. Graefe-Mody EU, Jungnik A, Ring A, Woerle H-J, Dugi KA. Evaluation of pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers. Int J Clin Pharmacol Ther. 2010; 48: 652-661.
13. Scheen AJ. Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet. 2010; 49: 573-588.
14. Friedrich C, Port A, Ring A, Graefe-Mody U, Giessmann T, Iovino M, et al. Linagliptin does not alter the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel (Microgynon®) in healthy adult female subjects. Abstract PI-68. Clin Pharmacol Ther. 2010; 87(Suppl 1): S31.
15. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005; 44: 1227-1246. (Pubitemid 41832565)
16. Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab. 2009; 10: 632-642.
17. Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements - a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009; 65: 365-375.
18. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994; 121: 676-683.
19. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165: 1095-1106. (Pubitemid 40720733)
20. Graefe-Mody U, Rose P, Ring A, Zander K, Iovino M, Woerle H-J. Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Drug Metab Pharmacokinet. 2011; Epub ahead of print.
21. Forst T, Uhlig-Laske B, Ring A, Graefe-Mody U, Friedrich C, Herbach K et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabet Med. 2010; 27: 1409-1419.
22. th Scientific Sessions, Orlando, Florida 25-29 June 2010. Available at: http://professional. diabetes.org/Abstracts-Display.aspx?TYP=1&CID=79496 (accessed 18 November 2010).
23. th Scientific Sessions, Orlando, Florida 25-29 June 2010. Available at: http://professional.diabetes.org/Abstracts-Display.aspx?TYP= 1&CID=79499 (accessed 18 November 2010).
24. Del Prato S, Barnett A, Huisman H, Neubacher D, Woerle H-J, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomised controlled trial. Diabetes Obes Metab. 2011; 13: 258-267.
25. Taskinen M-R, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 65-74.
26. th Annual Meeting, Stockholm, Sweden. 20-24 September 2010. Diabetologia. 2010; 53(Suppl 1): S326.
27. th Annual Meeting, Stockholm, Sweden. 20-24 September 2010. Diabetologia. 2010; 53(Suppl 1): S327.
28. th Scientific Sessions, Orlando, Florida 25-29 June 2010. Available at: http://professional.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=79641 (accessed 18 November 2010).
29. th Scientific Sessions, Orlando, Florida 25-29 June 2010. Available at: http://professional.diabetes.org/Abstracts- Display.aspx?TYP=1&CID=79579 (accessed 18 November 2010).
30. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet. 1986; 11: 483-504.
31. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003; 3: 221-230. (Pubitemid 37280710)
32. Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 2009; 49: 1157-1167.
33. He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M et al. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin. 2007; 23: 1131-1138. (Pubitemid 46799597)
34. Anderson DM, Shelley S, Crick N, Buraglio M. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. J Clin Pharmacol. 2002; 42: 1358-1365. (Pubitemid 35373606)
35. Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1999; 39: 495-500. (Pubitemid 29356470)
36. Kirchheiner J, Brockmöller J, Meineke I, Bauer S, Rohde W, Meisel C et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther. 2002; 71: 286-296. (Pubitemid 34311458)
37. Brockmöller J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics. 2000; 1: 125-151.